LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 98 of 166
Next
>>
>
2426 to 2450 of 4140 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Timepoint	Timepoint Unit	Mean Total Cell Count Before Treatment	Mean Total Cell Count After Treatment	Mean Total Control Cell Count	Mean Relative Cell Count	Mean Normalized Growth Rate Inhibition Value
BT-20	XMD16-144	0.12	uM	LJP5	72	hr	1097	1569	3846	0.4082	0.2182
BT-20	XMD16-144	0.37	uM	LJP5	72	hr	1097	1323	3846	0.3444	0.1093
BT-20	XMD16-144	1.11	uM	LJP5	72	hr	1097	1389	3846	0.3615	0.1394
BT-20	XMD16-144	3.33	uM	LJP5	72	hr	1097	1312	3846	0.3414	0.1040
BT-20	XMD16-144	10	uM	LJP5	72	hr	1097	1051	3846	0.2734	-0.0242
BT-20	Erlotinib	0.04	uM	LJP5	72	hr	1097	3377	3846	0.8772	0.8582
BT-20	Erlotinib	0.12	uM	LJP5	72	hr	1097	3281	3846	0.8528	0.8312
BT-20	Erlotinib	0.37	uM	LJP5	72	hr	1097	3329	3846	0.8654	0.8460
BT-20	Erlotinib	1.11	uM	LJP5	72	hr	1097	3165	3846	0.8242	0.7972
BT-20	Erlotinib	3.33	uM	LJP5	72	hr	1097	3231	3846	0.8406	0.8165
BT-20	Erlotinib	10	uM	LJP5	72	hr	1097	2595	3846	0.6753	0.6096
BT-20	Gefitinib	0.04	uM	LJP6	72	hr	1097	3523	3673	0.9592	0.9529
BT-20	Gefitinib	0.12	uM	LJP6	72	hr	1097	3197	3673	0.8705	0.8471
BT-20	Gefitinib	0.37	uM	LJP6	72	hr	1097	3297	3673	0.8980	0.8804
BT-20	Gefitinib	1.11	uM	LJP6	72	hr	1097	3142	3673	0.8550	0.8272
BT-20	Gefitinib	3.33	uM	LJP6	72	hr	1097	3134	3673	0.8531	0.8256
BT-20	Gefitinib	10	uM	LJP6	72	hr	1097	2640	3673	0.7190	0.6547
BT-20	Nilotinib	0.04	uM	LJP5	72	hr	1097	3963	3846	1.0314	1.0346
BT-20	Nilotinib	0.12	uM	LJP5	72	hr	1097	4002	3846	1.0414	1.0444
BT-20	Nilotinib	0.37	uM	LJP5	72	hr	1097	3882	3846	1.0100	1.0109
BT-20	Nilotinib	1.11	uM	LJP5	72	hr	1097	3875	3846	1.0078	1.0086
BT-20	Nilotinib	3.33	uM	LJP5	72	hr	1097	3734	3846	0.9709	0.9676
BT-20	Nilotinib	10	uM	LJP5	72	hr	1097	1040	3846	0.2708	-0.0290
BT-20	JNK-9L	0.04	uM	LJP6	72	hr	1097	2987	3673	0.8138	0.7764
BT-20	JNK-9L	0.12	uM	LJP6	72	hr	1097	2972	3673	0.8095	0.7715

|<
<<
Previous
Page 98 of 166
Next
>>
>
2426 to 2450 of 4140 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)